Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 115Recurrence 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasms, Plasma Cell 13Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Burkitt Lymphoma 7Lymphoma, B-Cell 4Lymphoma 4Smoldering Multiple Myeloma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Paraproteinemias 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia 2Fatigue 2Wrist Fractures 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Plasmacytoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pancreatic Neoplasms 1

Interventions

pomalidomide 1UE2343 1Dexamethasone 1Amyloid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Alzheimer Disease × Dexamethasone × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡